Spyre Therapeutics (SYRE) Total Debt (2023 - 2026)

Spyre Therapeutics has reported Total Debt for 4 years, with the latest figure at $50.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Debt rose 17.4% year-over-year to $50.3 million; the trailing twelve-month figure through Mar 2026 stood at $50.3 million (up 17.4% YoY), and the FY2025 full-year result was $22.8 million, down 9.01% from the prior year.
• Total Debt for Q1 2026 stood at $50.3 million, up from $22.8 million in the prior quarter.
• The five-year high for Total Debt was $164.4 million in Q2 2023, with the low at $1.4 million in Q4 2023.
• Historically, Total Debt has averaged $34.6 million across 4 years, with a median of $23.8 million in 2024.
• Annual changes were most pronounced in 2024 — Total Debt plunged 98.39% — and 2025, when it jumped 2168.94%.
• Spyre Therapeutics' Total Debt stood at $1.4 million in 2023, then soared by 1704.32% to $25.1 million in 2024, then slipped by 9.01% to $22.8 million in 2025, then surged by 120.25% to $50.3 million in 2026.
• The last three Total Debt figures came in at $50.3 million (Q1 2026), $22.8 million (Q4 2025), and $11.0 million (Q3 2025), per Business Quant data.